Interventions for Neuropsychiatric symptoms in Neurocognitive impairment due to Alzheimer's disease: A review of the literature

Harvard Review of Psychiatry

Volumn 23, Issue 5, 2015, Pages 377-393

  McClam, Tamela D ^a   Marano, Christopher M ^b   Rosenberg, Paul B ^b   Lyketsos, Constantine G ^b  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

aggression; agitation; Alzheimer's; depression; insomnia; neurocognitive disorders; neuropsychiatric symptoms; nonpharmacologic interventions; pharmacologic interventions

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL STIMULANT AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; COGNITIVE ENHANCER; DONEPEZIL; DRONABINOL; ESCITALOPRAM; MELATONIN; MEMANTINE; METHYLPHENIDATE; MIBAMPATOR; MIRTAZAPINE; MODAFINIL; NUTRACEUTICAL; OLANZAPINE; OMEGA 3 FATTY ACID; PRAZOSIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TOPIRAMATE; TRAZODONE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANTICONVULSANT THERAPY; ANXIETY; AROMATHERAPY; BRADYCARDIA; COGNITIVE DEFECT; COGNITIVE STIMULATION THERAPY; COMPLETE HEART BLOCK; CONSERVATIVE TREATMENT; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCONVULSIVE THERAPY; EXERCISE; FAINTNESS; HALLUCINATION; HEADACHE; HIP FRACTURE; HUMAN; INSOMNIA; MENTAL DISEASE; MENTAL HEALTH CARE; MINI MENTAL STATE EXAMINATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NIGHTMARE; NON INVASIVE PROCEDURE; ORTHOSTATIC HYPOTENSION; PARANOIA; PATIENT CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOCIAL INTERACTION; UNSPECIFIED SIDE EFFECT; VOMITING; AGED; COGNITION DISORDERS; COMPLICATION; FEMALE; MALE; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 84942022579     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000097     Document Type: Review

References (108)

1. Rabins PV, Lyketsos CG, Steele CD,. Practical dementia care. 2nd ed. New York: Oxford University Press, 2006.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: APA, 2013.
3. Mitchell SL, Teno JM, Kiely DK, The clinical course of advanced dementia. N Engl J Med 2009; 361: 1529-38.
4. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM,. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3: 186-91.
5. Hebert LE, Weuve J, Scherr PA, Evans DA,. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013; 80: 1778-83.
6. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM,. Monetary costs of dementia in the United States. N Engl J Med 2013; 368: 1326-34.
7. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N,. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996; 8 suppl 3: 497-500.
8. Steinberg M, Shao H, Zandi P, Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008; 23: 170-7.
9. Geda YE, Schneider LS, Gitlin LN, Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement 2013; 9: 602-8.
10. Lyketsos CG, Carrillo MC, Ryan JM, Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement 2011; 7: 532-9.
11. Sink KM, Covinsky KE, Barnes DE, Newcomer RJ, Yaffe K,. Caregiver characteristics are associated with neuropsychiatric symptoms of dementia. J Am Geriatr Soc 2006; 54: 796-803.
12. Peters ME, Rosenberg PB, Steinberg M, Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: the Cache County Study. Am J Geriatr Psychiatry 2013; 21: 1116-24.
13. Rabins PV, Schwartz S, Black BS, Predictors of progression to severe Alzheimer's disease in an incidence sample. Alzheimers Dement 2013; 9: 204-7.
14. Lyketsos CG, Miller DS,. Addressing the Alzheimer's disease crisis through better understanding, treatment, and eventual prevention of associated neuropsychiatric syndromes. Alzheimers Dement 2012; 8: 60-4.
15. Levy K, Lanctot KL, Farber SB, Li A, Herrmann N,. Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden? Drugs Aging 2012; 29: 167-79.
16. Kales HC, Gitlin LN, Lyketsos CG,. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc 2014; 62: 762-9.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA, 1994.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.,. text rev. Washington, DC: APA, 2000.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM,. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
20. Folstein MF, Folstein SE, McHugh PR,. "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
21. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J,. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
22. Cohen-Mansfield J,. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc 1986; 34: 722-7.
23. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA,. Cornell Scale for Depression in Dementia. Biol Psychiatry 1988; 23: 271-84.
24. Guy W,. Clinical Global Impression scale. The ECDEU assessment manual for psychopharmacology-revised. Rockville, MD: US Dept. of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch, 1976.
25. De Deyn PP, Carrasco MM, Deberdt W, Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 115-26.
26. Mintzer JE, Tune LE, Breder CD, Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 2007; 15: 918-31.
27. Streim JE, Porsteinsson AP, Breder CD, A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 2008; 16: 537-50.
28. Paleacu D, Barak Y, Mirecky I, Mazeh D,. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry 2008; 23: 393-400.
29. Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T,. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 2004; 19: 9-18.
30. Rosenberg PB, Drye LT, Martin BK, Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 2010; 18: 136-45.
31. Banerjee S, Hellier J, Dewey M, Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011; 378: 403-11.
32. Barak Y, Plopski I, Tadger S, Paleacu D,. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. Int Psychogeriatr 2011; 23: 1515-9.
33. Porsteinsson AP, Drye LT, Pollock BG, Effect of citalopram on agitation in Alzheimer disease: the CITAD randomized clinical trial. JAMA 2014; 311: 682-91.
34. Camargos EF, Louzada LL, Quintas JL, Naves JO, Louzada FM, Nobrega OT,. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry 2014; 22: 1565-74.
35. Tariot PN, Raman R, Jakimovich L, Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 2005; 13: 942-9.
36. Herrmann N, Lanctot KL, Rothenburg LS, Eryavec G,. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 23: 116-9.
37. Mowla A, Pani A,. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol 2010; 30: 40-3.
38. Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL,. Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the neurobehavioral rating scale. J Am Geriatr Soc 1992; 40: 549-55.
39. Overall JE, Gorham DR,. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812.
40. Macijauskiene J, Lesauskaite V,. Dementia with Lewy bodies: the principles of diagnostics, treatment, and management. Medicina (Kaunas) 2012; 48: 1-8.
41. US Food and Drug Administration. Information on conventional antipsychotics. 2008. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107211.htm
42. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC,. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013; 54: 1-13.
43. Steinberg M, Lyketsos CG,. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry 2012; 169: 900-6.
44. Schneider LS, Dagerman KS, Insel P,. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43.
45. Looper KJ,. Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics 2007; 48: 1-9.
46. Holroyd S, Overdyke JT,. Hyperammonemia associated with valproic acid use in elderly psychiatric patients. J Neuropsychiatry Clin Neurosci 2012; 24: 372-4.
47. Evans MD, Shinar R, Yaari R,. Reversible dementia and gait disturbance after prolonged use of valproic acid. Seizure 2011; 20: 509-11.
48. Masmoudi K, Gras-Champel V, Masson H, Andrejak M,. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006; 39: 9-12.
49. Dolder CR, Nealy KL,. The efficacy and safety of newer anticonvulsants in patients with dementia. Drugs Aging 2012; 29: 627-37.
50. Howard RJ, Juszczak E, Ballard CG, Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357: 1382-92.
51. Holmes C, Wilkinson D, Dean C, Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. Int J Geriatr Psychiatry 2007; 22: 380-1.
52. Fox C, Crugel M, Maidment I, Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One 2012; 7: e35185.
53. Herrmann N, Gauthier S, Boneva N, Lemming OM,. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. Int Psychogeriatr 2013; 25: 919-27.
54. Thompson S, Lanctot KL, Herrmann N,. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf 2004; 3: 425-40.
55. Grossberg GT, Manes F, Allegri RF, The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 2013; 27: 469-78.
56. Gill SS, Anderson GM, Fischer HD, Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 2009; 169: 867-73.
57. Wang LY, Shofer JB, Rohde K, Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 2009; 17: 744-51.
58. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D,. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 2011; 343: d4065.
59. Frakey LL, Salloway S, Buelow M, Malloy P,. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease. J Clin Psychiatry 2012; 73: 796-801.
60. Trzepacz PT, Cummings J, Konechnik T, Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. Int Psychogeriatr 2013; 25: 707-19.
61. Rosenberg PB, Lanctot KL, Drye LT, Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry 2013; 74: 810-6.
62. Grace J, Malloy PF,. Frontal Systems Behavior Scale: professional manual. Lutz, FL: Psychological Assessment Resources, 2001.
63. Ballon JS, Feifel D,. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006; 67: 554-66.
64. Wilens TE,. Mechanism of action of agents used in attention-deficit/hyperactivity disorder. J Clin Psychiatry 2006; 67 suppl 8: 32-8.
65. Marin RS, Biedrzycki RC, Firinciogullari S,. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991; 38: 143-62.
66. Schneider LS, Olin JT, Doody RS, Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 suppl 2: S22-32.
67. Rosendorff C,. Prazosin: severe side effects are dose-dependent. Br Med J 1976; 2: 508.
68. Morton WA, Stockton GG,. Methylphenidate abuse and psychiatric side effects. Prim Care Companion J Clin Psychiatry 2000; 2: 159-64.
69. Kalra EK,. Nutraceutical-definition and introduction. AAPS PharmSci 2003; 5: E25.
70. Freund-Levi Y, Basun H, Cederholm T, Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008; 23: 161-9.
71. Gehrman PR, Connor DJ, Martin JL, Shochat T, Corey-Bloom J, Ancoli-Israel S,. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry 2009; 17: 166-9.
72. Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, Hoerr R,. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health 2009; 13: 183-90.
73. Burns A, Perry E, Holmes C, A double-blind placebo-controlled randomized trial of melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. Dement Geriatr Cogn Disord 2011; 31: 158-64.
74. Furuhashi Y, Shin K,. Risperidone versus yokukansan in the treatment of severe Alzheimer's disease. Int J Clin Med 2011; 2: 166-70.
75. Wade AG, Farmer M, Harari G, Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging 2014; 9: 947-61.
76. Mischoulon D, Freeman MP,. Omega-3 fatty acids in psychiatry. Psychiatr Clin North Am 2013; 36: 15-23.
77. Montgomery SA, Asberg M,. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
78. Lyseng-Williamson KA,. Melatonin prolonged release: in the treatment of insomnia in patients aged >/=55 years. Drugs Aging 2012; 29: 911-23.
79. Corrigan JD,. Development of a scale for assessment of agitation following traumatic brain injury. J Clin Exp Neuropsychol 1989; 11: 261-77.
80. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ,. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
81. Perry E, Howes MJ,. Medicinal plants and dementia therapy: herbal hopes for brain aging? CNS Neurosci Ther 2011; 17: 683-98.
82. Hamilton M,. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
83. Rosen J, Burgio L, Kollar M, A user-friendly instrument for rating agitation in dementia patients. Am J Geriatr Psychiatry 1994; 2: 52-9.
84. Bent S, Goldberg H, Padula A, Avins AL,. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. J Gen Intern Med 2005; 20: 657-61.
85. Monji A, Takita M, Samejima T, Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 308-11.
86. Dowling GA, Graf CL, Hubbard EM, Luxenberg JS,. Light treatment for neuropsychiatric behaviors in Alzheimer's disease. West J Nurs Res 2007; 29: 961-75.
87. Williams CL, Tappen RM,. Exercise training for depressed older adults with Alzheimer's disease. Aging Ment Health 2008; 12: 72-80.
88. Guetin S, Portet F, Picot MC, Effect of music therapy on anxiety and depression in patients with Alzheimer's type dementia: randomised, controlled study. Dement Geriatr Cogn Disord 2009; 28: 36-46.
89. Niu YX, Tan JP, Guan JQ, Zhang ZQ, Wang LN,. Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial. Clin Rehabil 2010; 24: 1102-11.
90. McCurry SM, Pike KC, Vitiello MV, Logsdon RG, Larson EB, Teri L,. Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer's disease: results of a randomized, controlled trial. J Am Geriatr Soc 2011; 59: 1393-402.
91. Terman M, Terman JS,. Bright light therapy: side effects and benefits across the symptom spectrum. J Clin Psychiatry 1999; 60.
92. Tappen R, Williams C,. Alzheimer's mood scale: validity and reliability. Abstract presented at the annual scientific meeting of the Gerontological Society of America, San Francisco, CA, 1999.
93. Hill JL, Tariot PN, Newhouse PA, Mueller EA, Cohen RM,. A new scale for the assessment of depressed mood in demented patients. Am J Psychiatry 1988; 145: 955-9.
94. Lawton MP, Van Haitsma K, Klapper J,. Observed affect in nursing home residents with Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci 1996; 51: P3-14.
95. Hamilton M,. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5.
96. Yesavage JA, Brink TL, Rose TL, Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17: 37-49.
97. Tractenberg RE, Singer CM, Cummings JL, Thal LJ,. The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J Sleep Res 2003; 12: 331-7.
98. Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM,. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry 2014; 22: 415-9.
99. Ujkaj M, Davidoff DA, Seiner SJ, Ellison JM, Harper DG, Forester BP,. Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia. Am J Geriatr Psychiatry 2012; 20: 61-72.
100. Acharya D, Harper DG, Achtyes ED, Safety and utility of acute electroconvulsive therapy for agitation and aggression in dementia. Int J Geriatr Psychiatry 2015; 30: 265-73.
101. Rabins PV, Blacker D, Rovner BW, APA Work Group on Alzheimer's Disease and other Dementias, American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry 2007; 164 (12 suppl): 5-56.
102. Consensus statement on improving the quality of mental health care in U.S. nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003; 51: 1287-98.
103. Schneider LS, Tariot PN, Dagerman KS, Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525-38.
104. Sultzer DL, Davis SM, Tariot PN, Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165: 844-54.
105. Rosenberg PB, Mielke MM, Han D, The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatry 2012; 27: 1248-57.
106. Tariot PN, Erb R, Podgorski CA, Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54-61.
107. Sink KM, Holden KF, Yaffe K,. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293: 596-608.
108. Tampi RR, Tampi DJ,. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen 2014; 29: 565-74.